Patent Application
20120029036
The invention relates to a pharmaceutical composition comprising pyridyl cyanoguanidine, process for preparing the same and use thereof.
It was initially found that pyridyl cyanoguanidine such as pinadicil (N-1,2,2-trimethylpropyl-N′-cyano-N″-(4-pyridyl)guanidine) is a potassium channel opener and therefore pyridyl cyanoguanidine was developed as a antihypertensive agent. If the side chain of pinadicil was replaced with longer aryl group-containing side chain, pyridyl cyanoguanidine will lose the antihypertensive activity. However, in another aspect, it was found that such pyridyl cyanoguanidine has the antitumor activity when it is administered orally in a rat model with Yoshida ascitic tumor.
Various kinds of pyridyl cyanoguanidines with antiproliferative activities are disclosed in such as EP 660823, WO 98/54141, WO 98/54143, WO 98/54144, WO 98/54145, WO 00/61559 and WO 00/61561, WO 98/54146, WO 2002/094813, U.S. Pat. No. 5,696,140. The structure-activity relation (SAR) of such compounds is discussed in C. Schou et al., Bioorganic and Medicinal Chemistry Letters 7(24), 1997, 3095-3100, wherein the antiproliferative effects of a large number of pyridyl cyanoguanidines on various human lung cancer and breast cancer cell lines as well as normal human fibroblasts have been tested in vitro. In vivo tests for the compounds have also been carried out using nude mice with human lung cancer tumor xenotransplantation. A specific compound (N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine) with high in vitro antiproliferative activity and high antitumor activity in nude mice model was selected according to the SAR analysis.
Further test results of in vitro and in vivo tests of the compound N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine are reported in P-J V Hjarnaa et al., Cancer Res. 59, 1999, 5751-5757. The compound exhibits comparative in vitro efficacy with cytostatic agents daunorubicin and paclitaxel as control, and also shows significantly lower antiproliferative activity to normal human endothelial cells. In the in vivo test carried out with nude mice transplanted human tumour cells, the compound shows potent antitumour activity and can also oppose tumor cells with drug-tolerance to conventional antitumor drugs such as paclitaxel.
Although as stated above pyridyl cyanoguanidine is a great promising antitumor medicament and has the quite notable antitumor activity, pyridyl cyanoguanidine has high lipotropy and therefore is an insoluble compound. CN 01819244.0 discloses that the solubility of N-(6-(4-chlorophenoxy)-hexyl)-N′-cyano-N″-(4-pyridyl)-guanidine in water is 0.0002 mg/ml, which means that the compound generally can only be administered orally. However, there exists a big issue as to the compliance of patients when the drugs are administered orally because many patients suffering from cancers are very weak. Therefore, a conventional way to increase the solubility of an insoluble compound is to prepare a water-soluble prodrug. Prodrugs of pyridyl cyanoguanidine are disclosed in WO 2003/097602, WO 2003/097601 and WO 2002/042265.
Since β-cyclodextrin (β-CD) was obtained successfully from fermentation liquor by S. Dentin firstly in 1903, a great progress in the preparation, property and application of cyclodextrins has been achieved by researchers. Therefore, β-cyclodextrin has been used in a variety of fields. The pharmaceutical application of cyclodextrins and derivatives thereof cause great interests of researchers. Pharmaceutical cyclodextrin clathrates increasingly exhibit unique properties and application values in improving solubility, dissolution rate and bioavailability of a medicament. β-CD has been recorded as oral excipients in pharmacopoeia of the United States, Japan and China, etc.
The invention discloses a composition comprising at least one of compounds of formula (I) and a cyclodextrin, a cyclodextrin derivative and/or other surfactants with solubilization, process for preparing the same and use thereof,
wherein
the connecting position with the pyridine ring is at the 3- or 4-position of the pyridine ring;
R1 represents 0 to 4 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, NR3R4, OR3, COOC1-4 alkyl, C1-4 alkyl or CN;
X represents C4-20 alkylene;
Y represents a covalent bond, O, S, S(O), S(O)2, NR3, —OC(O)—, —C(O)O—, —NHC(O)— or —C(O)NH—;
Q represents —C(O)OC1-6 alkyl, a five- or six-membered aromatic heterocyclic ring containing 1 to 2 nitrogen atoms, a compound of formula (II) or a compound of formula (III), wherein the dashed lines in the compound of formula (II) and the compound of formula (III) represent the connecting position of chemical bonds, and R1 in the compound of formula (III) is defined as R1 in the compound of formula (I),
R2 represents 0 to 5 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, NR3R4, OR3, COOC1-4 alkyl, C1-4 alkyl, SC1-4 alkyl, S(O)C1-4 alkyl, S(O)2C1-4 alkyl or CN.
Unless otherwise specified, R3 and R4 in the invention each represent H, C1-4 alkyl, C(O)C1-4 alkyl or S(O)2C1-4 alkyl, respectively.
C1-4 alkyl in the invention represents a branched or linear, saturated or unsaturated monovalent alkyl containing 1 to 4 carbon atoms, which can be substituted with 0 to 3 following substituents: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, COOH, C(O)NR3R4, NR3R4, a phenyl or a substituted phenyl, wherein the substituted phenyl refers to a phenyl containing 1 to 4 following identical or different groups: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, R3, COOH, C(O)NR3R4 or NR3R4.
C1-6 alkyl in the invention represents a branched or linear, saturated or unsaturated monovalent alkyl containing 1 to 6 carbon atoms, which can be substituted with 0 to 3 following groups: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, COOH, C(O)NR3R4, NR3R4, a phenyl or a substituted phenyl, wherein the substituted phenyl refers to a phenyl containing 1 to 4 following identical or different groups: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, R3, COOH, C(O)NR3R4 or NR3R4.
C4-20 alkylene in the invention represents a branched or linear, saturated or unsaturated divalent alkyl containing 4 to 20 carbon atoms, which can be substituted with 0 to 6 following identical or different groups: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, COOH, C(O)NR3R4, NR3R4, a phenyl or a substituted phenyl, wherein the substituted phenyl refers to a phenyl containing 1 to 4 following identical or different groups: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, R3, COOH, C(O)NR3R4 or NR3R4.
The five- or six-membered aromatic heterocyclic ring containing 1 to 2 nitrogen atoms in the invention represents pyrrolyl, pyridyl or pyrimidinyl, which can be substituted with 0 to 4 following identical same or different groups: OH, F, Cl, NO2, CN, SH, NHC(O)NH2, OR3, SR3, COOH, C(O)NR3R4 or NR3R4.
The composition comprising a compound of formula (I) provided in the invention significantly increase the solubility of the compound of formula (I) in an aqueous solution and therefore it gives more options for clinical practice of the compound of formula (I).
In the composition comprising at least one of a compound of formula (I) in the invention, the compound of formula (I) refers to a compound of formula (I), a pharmaceutically acceptable salt of a compound of formula (I), a solvate of a compound of formula (I), a solvate of a pharmaceutically acceptable salt of a compound of formula (I), a tautomer of a compound of formula (I), a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), a solvate of a tautomer of a compound of formula (I) or a solvate of a pharmaceutically acceptable salt of a tautomer of a compound of formula (I).
A tautomer of a compound of formula (I) as described in the invention includes, but is not limited to the structure of a compound of formula (IV):
wherein
the connecting position with the pyridine ring is at the 3- or 4-position of the pyridine ring;
R1 represents 0 to 4 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, NR3R4, OR3, COOC1-4 alkyl, C1-4 alkyl or CN;
X represents C4-20 alkylene;
Y represents a covalent bond, O, S, S(O), S(O)2, NR3, —OC(O)—, —C(O)O—, —NHC(O)— or —C(O)NH—;
Q represents —C(O)OC1-6 alkyl, a five- or six-membered aromatic heterocyclic ring containing 1 to 2 nitrogen atoms, a compound of formula (II) or a compound of formula (III), wherein the dashed lines in the compound of formula (II) and the compound of formula (III) represent the connecting position of chemical bonds, and R1 in the compound of formula (III) is defined as R1 in the compound of formula (I),
R2 represents 0 to 5 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, NR3R4, OR3, COOC1-4 alkyl, C1-4 alkyl, SC1-4 alkyl, S(O)C1-4 alkyl, S(O)2C1-4 alkyl or CN;
Unless otherwise specified, R3 and R4 in the invention each represent H, C1-4 alkyl, C(O)C1-4 alkyl or S(O)2C1-4 alkyl, respectively.
A composition provided in the invention is prepared with at least one of a compound of formula (I), a pharmaceutically acceptable salt of a compound of formula (I), a solvate of a compound of formula (I), a solvate of a pharmaceutically acceptable salt of a compound of formula (I), a tautomer of a compound of formula (I), a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), a solvate of a tautomer of a compound of formula (I) or a solvate of a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), and a cyclodextrin and/or a cyclodextrin derivative.
A composition provided in the invention is prepared with at least one of a compound of formula (I), a pharmaceutically acceptable salt of a compound of formula (I), a solvate of a compound of formula (I), a solvate of a pharmaceutically acceptable salt of a compound of formula (I), a tautomer of a compound of formula (I), a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), a solvate of a tautomer of a compound of formula (I) or a solvate of a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), and a surfactant with solubilization.
Another composition provided in the invention is prepared with at least one of a compound of formula (I), a pharmaceutically acceptable salt of a compound of formula (I), a solvate of a compound of formula (I), a solvate of a pharmaceutically acceptable salt of a compound of formula (I), a tautomer of a compound of formula (I), a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), a solvate of a tautomer of a compound of formula (I) or a solvate of a pharmaceutically acceptable salt of a tautomer of a compound of formula (I), and a cyclodextrin and/or a cyclodextrin derivative and a surfactant with solubilization.
Where a composition provided in the invention comprises a cyclodextrin or a cyclodextrin derivative, the cyclodextrin or cyclodextrin derivative is selected one or more than one of the following: α-cyclodextrin, β-cyclodextrin (β-CD), γ-cyclodextrin, δ-cyclodextrin, (C1-4 alkyl)-α-cyclodextrin, (C1-4 alkyl)-β-cyclodextrin, (C1-4 alkyl)-γ-cyclodextrin, (hydroxy-C1-4 alkyl)-α-cyclodextrin, (hydroxy-C1-4 alkyl)-β-cyclodextrin, (hydroxy-C1-4 alkyl)-γ-cyclodextrin, (carboxy-C1-4 alkyl)-α-cyclodextrin, (carboxy-C1-4 alkyl)-β-cyclodextrin, (carboxy-C1-4 alkyl)-γ-cyclodextrin, diethylaminoethyl-α-cyclodextrin, diethylaminoethyl-β-cyclodextrin, diethylaminoethyl-γ-cyclodextrin, dihydroxy (C1-4 alkyl)-α-cyclodextrin, dihydroxy (C1-4 alkyl)-β-cyclodextrin, dihydroxy (C1-4 alkyl)-γ-cyclodextrin, sulfobutylether-α-cyclodextrin, sulfobutylether-β-cyclodextrin and sulfobutylether-γ-cyclodextrin.
The cyclodextrin or cyclodextrin derivative suitable for preparing a pharmaceutical composition comprising a compound of formula (I) is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-CD, hydroxypropyl-β-CD, dihydroxypropyl-β-CD, sulfobutylether-β-CD, methyl-β-CD, dimethyl-β-CD, randomly dimethylated-β-CD, randomly methylated-β-CD, carboxy methyl-β-CD, carboxy methylethyl-β-CD, diethyl-β-CD, tris-O-methyl-β-CD, tris-O-ethyl-β-CD, tris-O-butyryl-β-CD, tris-O-valeryl-β-CD, bis-O-caproyl-β-CD, glucosyl-β-CD, maltosyl-β-CD, maltotriosyl-β-CD, succinyl-dimethyl-β-CD, maleyl-dimethyl-β-CD, sulfopropyl-β-CD, 6-carboxymethyl-β-CD or hydroxypropyl-γ-cyclodextrin. The cyclodextrin or cyclodextrin derivative more suitable for preparing a pharmaceutical composition comprising a compound of formula (I) is α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethyl-β-CD, hydroxypropyl-β-CD, sulfobutylether-β-CD, methyl-β-CD, dimethyl-β-CD, carboxy methyl-β-CD, glucosyl-β-CD, maltosyl-β-CD, succinyl-dimethyl-β-CD, maleyl-dimethyl-β-CD, sulfopropyl-β-CD or hydroxypropyl-γ-cyclodextrin. The cyclodextrin or cyclodextrin derivative particularly suitable for preparing a pharmaceutical composition comprising a compound of formula (I) are: β-cyclodextrin, hydroxyethyl-β-CD, hydroxypropyl-β-CD, sulfobutylether-β-CD, glucosyl-β-CD, sulfopropyl-β-CD or hydroxypropyl-γ-cyclodextrin.
Where an α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin in the invention is substituted, the substitution can be any substitution suitable for a pharmaceutical excipient, which may be a single substitution or a combination of different substitutions. For example, the substitution range of sulfobutylether-β-CD may be from 1 to 20. A sulfobutylether-β-CD having a substitution of 7 may be a sulfobutylether-β-CD having a single substitution of 7 or a mixture of sulfobutylether-β-CDs having different substitutions but a mean substitution of 7. The appropriate substitution range of sulfobutylether-β-CD suitable for preparing a composition with a compound of formula (I) is from 3 to 8, more appropriate substitution range of sulfobutylether-β-CD suitable for preparing a composition with a compound of formula (I) is from 5 to 8, particularly appropriate substitution range of sulfobutylether-β-CD suitable for preparing a composition with a compound of formula (I) is from 6 to 8, the most appropriate substitution range of sulfobutylether-β-CD suitable for preparing a composition with a compound of formula (I) is from 6 to 7.1. Where an α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin in the invention is substituted, the substitution can be took place at any possible positions, and can be a combination of different positions. For example, a hydroxypropyl-β-CD can be substituted at the 2-position, i.e. 2-hydroxypropyl-β-CD; or at the 3-position, i.e. 3-hydroxypropyl-β-CD; or at 6-position, i.e. 6-hydroxypropyl-β-CD; or a mixture of hydroxypropyl-β-CDs substituted at the 2-position, 3-position and/or 6-position. Unless otherwise specified, sulfobutylether-β-CD and hydroxypropyl-β-CD used in the invention are a mixture.
Where a pharmaceutical compositions disclosed in the invention comprises a surfactant with solubilization, the surfactant with solubilization is selected from one or more than one of the following: Tween-20, Tween-80, Tween-40, polyethylene glycol, polyoxyethylene castor oil, polyoxyethylene hydrogenated castor oil, polyvinylpyrrolidone, poloxamer(poloxamer), lecithin, soy lecithin, cephalin, phosphatidic acid, dipalmitoylphosphatidylcholine, hydrophosphatidyl ethanolamines, phosphatidylserine, cholesterol, diamino cholesterol, soy sterylacylglucoside, soysterol or ergosterol.
Compounds of formula (I) suitable for preparing a composition as a pharmaceutically active component are those compounds, in which R1 represents 0 to 4 identical or different F, Cl, OH, NO2, CF3, CH3, CHF2 or CH2F. Compounds of formula (I) more suitable for preparing a composition as a pharmaceutically active components are those compounds, in which R1 represents 0 to 2 identical or different F, Cl, OH, CH3 or CF3. Compounds of formula (I) particularly suitable for preparing a composition as a pharmaceutically active component are those compounds, in which R1 represents 0 to 1 identical or different of F or OH.
Compounds of formula (I) suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Q represents a compound of formula (II) and R2 represents 0 to 5 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, CHF2, CH2F, N(CH3)2, N(CH2CH3)2, N(CH3)(CH2CH3), CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, OCH3, OCH2CH3, OCH(CH3)2, COOCH3, COOCH2CH3, COOCH(CH3)2 or CN. Compounds of formula (I) more suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Q represents a compound of formula (II) and R2 represents 0 to 3 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, CHF2, CH2F, N(CH3)2, N(CH2CH3)2, N(CH3)(CH2CH3), CH3, CH2CH3, OCH3, OCH2CH3, COOCH3, COOCH2CH3 or CN. Compounds of formula (I) particularly suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Q represents a compound of formula (II) and R2 represents 0 to 3 following identical or different substituents: F, Cl, Br, NO2, OH, COOH, CF3, CHF2, CH2F, N(CH3)2, N(CH2CH3)2, CH3, CH2CH3, OCH3, OCH2CH3 or CN.
Compounds of formula (I) suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Q represents a compound of formula (III) and R1 represents 0 to 4 identical or different substituents: F, Cl, OH, NO2, CF3, CH3, CHF2 or CH2F. Compounds of formula (I) more suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Q represents a compound of formula (III) and R1 represents 0 to 2 identical or different substituents: F, Cl, OH, CH3 or CF3. Compounds of formula (I) particularly suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Q represents a compound of formula (III) and R1 represents 0 to 1 identical or different substituent: F or OH.
Compounds of formula (I) suitable for preparing a composition as a pharmaceutically active component are those compounds, in which X represents C4-15 alkylene. Compounds of formula (I) more suitable for preparing a composition as a pharmaceutically active component are those compounds, in which X represents C4-10 alkylene. Compounds of formula (I) particularly suitable for preparing a composition as a pharmaceutically active component are those compounds, in which X represents 1,4-butylidene, 1,5-pentylidene, 1,6-hexylidene, 1,7-heptylidene, 1,8-octylidene or 1,9-nonylidene.
Compounds of formula (I) suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Y represents O, S, NH, —OC(O)—, —C(O)O—, —C(O)—, —NHC(O)— or —C(O)NH—. Compounds of formula (I) more suitable for preparing a composition as a pharmaceutically active component are those compounds, in which Y represents O.
In a composition comprising a compound of formula (I) in the invention, the molar ratio of the compound of formula (I) to the cyclodextrin, the cyclodextrin derivative or the surfactant with solubilization in the composition is the range of from 1:1000 to 200:1.
The representative compounds of a compound of formula (I) which can be prepared in a composition in the invention include, but are not limited to the following compounds:
1) N-cyano-N′-(6-phenoxyhexyl)-N″-(3-pyridyl)guanidine,
2) N-cyano-N′-(6-(p-chlorophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
3) N-cyano-N′-(6-(o-chlorophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
4) N-cyano-N′-(6-(o-methoxyphenoxy)hexyl)-N″-(3-pyridyl)guanidine,
5) N-cyano-N′-(6-(o-nitrophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
6) N-cyano-N′-(6-(m-chlorophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
7) N-cyano-N′-(6-(m-methoxyphenoxy)hexyl)-N″-(3-pyridyl)guanidine,
8) N-cyano-N′-(6-(m-nitrophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
9) N-cyano-N′-(6-(p-fluorophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
10) N-cyano-N′-(6-(m-fluorophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
11) N-cyano-N′-(6-(o-fluorophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
12) N-cyano-N′-(6-(p-fluorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
13) N-cyano-N′-(6-(m-fluorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
14) N-cyano-N′-(6-(o-fluorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
15) N-cyano-N′-(6-(p-methoxyphenoxy)hexyl)-N″-(3-pyridyl)guanidine,
16) N-cyano-N′-(6-(p-nitrophenoxy)hexyl)-N″-(3-pyridyl)guanidine,
17) N-cyano-N′-(6-(p-nitrophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
18) N-cyano-N′-(6-(p-methoxyphenoxy)hexyl)-N″-(4-pyridyl)guanidine,
19) N-cyano-N′-(6-(p-chlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
20) N-cyano-N′-(6-(m-nitrophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
21) N-cyano-N′-(6-(m-methoxyphenoxy)hexyl)-N″-(4-pyridyl)guanidine,
22) N-cyano-N′-(6-(m-chlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
23) N-cyano-N′-(6-(o-nitrophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
24) N-cyano-N′-(6-(o-methoxyphenoxy)hexyl)-N″-(4-pyridyl)guanidine,
25) N-cyano-N′-(6-(o-chlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
26) N-cyano-N′-(6-phenoxyhexyl)-N″-(4-pyridyl)guanidine,
27) N-cyano-N′-(6-(2,4-dichlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
28) N-cyano-N′-(6-(2,4,5-trichlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
29) N-cyano-N′-(7-phenoxyheptyl)-N″-(3-pyridyl)guanidine,
30) N-cyano-N′-(7-phenoxyheptyl)-N″-(4-pyridyl)guanidine,
31) N-cyano-N′-(7-(p-fluorophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
32) N-cyano-N′-(7-(o-fluorophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
33) N-cyano-N′-(7-(m-fluorophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
34) N-cyano-N′-(7-(p-fluorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
35) N-cyano-N′-(7-(o-fluorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
36) N-cyano-N′-(7-(m-fluorophenoxy)heptyl)-N″-(4-pyridyl)guanidine
37) N-cyano-N′-(7-(o-chlorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
38) N-cyano-N′-(7-(o-chlorophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
39) N-cyano-N′-(7-(o-methoxyphenoxy)heptyl)-N″-(3-pyridyl)guanidine,
40) N-cyano-N′-(7-(o-methoxyphenoxy)heptyl)-N″-(4-pyridyl)guanidine,
41) N-cyano-N′-(7-(o-nitrophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
42) N-cyano-N′-(7-(o-nitrophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
43) N-cyano-N′-(7-(m-chlorophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
44) N-cyano-N′-(7-(m-chlorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
45) N-cyano-N′-(7-(m-methoxyphenoxy)heptyl)-N″-(4-pyridyl)guanidine,
46) N-cyano-N′-(7-(m-methoxyphenoxy)heptyl)-N″-(3-pyridyl)guanidine,
47) N-cyano-N′-(7-(m-nitrophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
48) N-cyano-N′-(7-(m-nitrophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
49) N-cyano-N′-(7-(p-chlorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
50) N-cyano-N′-(7-(p-chlorophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
51) N-cyano-N′-(7-(p-methoxyphenoxy)heptyl)-N″-(3-pyridyl)guanidine,
52) N-cyano-N′-(7-(p-methoxyphenoxy)heptyl)-N″-(4-pyridyl)guanidine,
53) N-cyano-N′-(7-(p-nitrophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
54) N-cyano-N′-(7-(p-nitrophenoxy)heptyl)-N″-(3-pyridyl)guanidine,
55) N-cyano-N′-(5-(p-fluorophenoxy)pentyl)-N″-(3-pyridyl)guanidine,
56) N-cyano-N′-(5-(o-fluorophenoxy)pentyl)-N″-(3-pyridyl)guanidine,
57) N-cyano-N′-(5-(m-fluorophenoxy)pentyl)-N″-(3-pyridyl)guanidine,
58) N-cyano-N′-(5-(p-fluorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
59) N-cyano-N′-(5-(o-fluorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
60) N-cyano-N′-(5-(m-fluorophenoxy)pentyl)-N″-(4-pyridyl)guanidine
61) N-cyano-N′-(5-(p-chlorophenoxy)pentyl)-N″-(3-pyridyl)guanidine,
62) N-cyano-N′-(5-phenoxypentyl)-N″-(3-pyridyl)guanidine,
63) N-cyano-N′-(5-phenoxypentyl)-N″-(4-pyridyl)guanidine,
64) N-cyano-N′-(5-(p-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
65) N-cyano-N′-(5-(p-methoxyphenoxy)pentyl)-N″-(3-pyridyl)guanidine,
66) N-cyano-N′-(5-(o-chlorophenoxy)pentyl)-N″-(3-pyridyl)guanidine,
67) N-cyano-N′-(5-(m-chlorophenoxy)pentyl)-N″-(3-pyridyl)guanidine,
68) N-cyano-N′-(5-(p-methoxyphenoxy)pentyl)-N″-(4-pyridyl)guanidine,
69) N-cyano-N′-(5-(o-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
70) N-cyano-N′-(5-(m-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine
71) N-cyano-N′-(8-(p-fluorophenoxy)octyl)-N″-(3-pyridyl)guanidine,
72) N-cyano-N′-(8-(o-fluorophenoxy)octyl)-N″-(3-pyridyl)guanidine,
73) N-cyano-N′-(8-(m-fluorophenoxy)octyl)-N″-(3-pyridyl)guanidine,
74) N-cyano-N′-(8-(p-fluorophenoxy)octyl)-N″-(4-pyridyl)guanidine,
75) N-cyano-N′-(8-(o-fluorophenoxy)octyl)-N″-(4-pyridyl)guanidine,
76) N-cyano-N′-(8-(m-fluorophenoxy)octyl)-N″-(4-pyridyl)guanidine,
77) N-cyano-N′-(8-(p-chlorophenoxy)octyl)-N″-(4-pyridyl)guanidine,
78) N-cyano-N′-(8-(p-chlorophenoxy)octyl)-N″-(3-pyridyl)guanidine,
79) N-cyano-N′-(8-phenoxyoctyl)-N″-(3-pyridyl)guanidine,
80) N-cyano-N′-(8-phenoxyoctyl)-N″-(4-pyridyl)guanidine,
81) N-cyano-N′-(10-phenoxydecyl)-N″-(4-pyridyl)guanidine,
82) N-cyano-N′-(10-phenoxydecyl)-N″-(3-pyridyl)guanidine,
83) N-cyano-N′-(10-(p-chlorophenoxy)decyl)-N″-(3-pyridyl)guanidine,
84) N-cyano-N′-(10-(o-chlorophenoxy)decyl)-N″-(3-pyridyl)guanidine,
85) N-cyano-N′-(10-(m-chlorophenoxy)decyl)-N″-(3-pyridyl)guanidine,
86) N-cyano-N′-(10-(p-fluorophenoxy)decyl)-N″-(3-pyridyl)guanidine,
87) N-cyano-N′-(10-(m-fluorophenoxy)decyl)-N″-(3-pyridyl)guanidine,
88) N-cyano-N′-(10-(o-fluorophenoxy)decyl)-N″-(3-pyridyl)guanidine,
89) N-cyano-N′-(10-(p-methoxyphenoxy)decyl)-N″-(3-pyridyl)guanidine,
90) N-cyano-N′-(10-(m-methoxyphenoxy)decyl)-N″-(3-pyridyl)guanidine,
91) N-cyano-N′-(10-(o-methoxyphenoxy)decyl)-N″-(3-pyridyl)guanidine,
92) N-cyano-N′-(10-(p-nitrophenoxy)decyl)-N″-(3-pyridyl)guanidine,
93) N-cyano-N′-(10-(o-nitrophenoxy)decyl)-N″-(3-pyridyl)guanidine,
94) N-cyano-N′-(10-(m-nitrophenoxy)decyl)-N″-(3-pyridyl)guanidine,
95) N-cyano-N′-(10-(p-chlorophenoxy)decyl)-N″-(4-pyridyl)guanidine,
96) N-cyano-N′-(10-(o-chlorophenoxy)decyl)-N″-(4-pyridyl)guanidine,
97) N-cyano-N′-(10-(m-chlorophenoxy)decyl)-N″-(4-pyridyl)guanidine,
98) N-cyano-N′-(10-(p-fluorophenoxy)decyl)-N″-(4-pyridyl)guanidine,
99) N-cyano-N′-(10-(m-fluorophenoxy)decyl)-N″-(4-pyridyl)guanidine,
100) N-cyano-N′-(10-(o-fluorophenoxy)decyl)-N″-(4-pyridyl)guanidine,
101) N-cyano-N′-(10-(p-methoxyphenoxy)decyl)-N″-(4-pyridyl)guanidine,
102) N-cyano-N′-(10-(m-methoxyphenoxy)decyl)-N″-(4-pyridyl)guanidine,
103) N-cyano-N′-(10-(o-methoxyphenoxy)decyl)-N″-(4-pyridyl)guanidine,
104) N-cyano-N′-(10-(p-nitrophenoxy)decyl)-N″-(4-pyridyl)guanidine,
105) N-cyano-N′-(10-(o-nitrophenoxy)decyl)-N″-(4-pyridyl)guanidine,
106) N-cyano-N′-(10-(m-nitrophenoxy)decyl)-N″-(4-pyridyl)guanidine,
107) N-cyano-N′-(12-phenoxydodecyl)-N″-(4-pyridyl)guanidine,
108) N-cyano-N′-(12-phenoxydodecyl)-N″-(3-pyridyl)guanidine,
109) N-cyano-N′-(12-(p-chlorophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
110) N-cyano-N′-(12-(o-chlorophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
111) N-cyano-N′-(12-(m-chlorophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
112) N-cyano-N′-(12-(p-fluorophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
113) N-cyano-N′-(12-(m-fluorophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
114) N-cyano-N′-(12-(o-fluorophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
115) N-cyano-N′-(12-(p-methoxyphenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
116) N-cyano-N′-(12-(m-methoxyphenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
117) N-cyano-N′-(12-(o-methoxyphenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
118) N-cyano-N′-(12-(p-nitrophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
119) N-cyano-N′-(12-(o-nitrophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
120) N-cyano-N′-(12-(m-nitrophenoxy)dodecyl)-N″-(3-pyridyl)guanidine,
121) N-cyano-N′-(12-(p-chlorophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
122) N-cyano-N′-(12-(o-chlorophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
123) N-cyano-N′-(12-(m-chlorophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
124) N-cyano-N′-(12-(p-fluorophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
125) N-cyano-N′-(12-(m-fluorophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
126) N-cyano-N′-(12-(o-fluorophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
127) N-cyano-N′-(12-(p-methoxyphenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
128) N-cyano-N′-(12-(m-methoxyphenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
129) N-cyano-N′-(12-(o-methoxyphenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
130) N-cyano-N′-(12-(p-nitrophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
131) N-cyano-N′-(12-(o-nitrophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
132) N-cyano-N′-(12-(m-nitrophenoxy)dodecyl)-N″-(4-pyridyl)guanidine,
133) 1,12-bis(N′-cyano-N″-4-pyridylguanidine)dodecane,
134) N-(12-(tert-butoxycarbonylamino)dodecyl)-N′-cyano-N″-(4-pyridyl)guanidine,
135) N-(6-((4-chlorobenzoic acid)ester)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
136) N-cyano-N′-(6-(2-chloro-4-fluorophenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
137) N-cyano-N′-(6-(o-bromophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
138) N-cyano-N′-(6-((2,6-dichlorophenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
139) N-cyano-N′-(6-((2,4,6-trichlorophenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
140) N-cyano-N′-(6-(o-trifluoromethoxyphenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
141) N-cyano-N′-(5-(o-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
142) N-cyano-N′-(7-(o-chlorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
143) N-cyano-N′-(5-(p-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
144) N-cyano-N′-(8-((o-methoxyphenyl)oxo)octyl)-N″-(4-pyridyl)guanidine,
145) N-cyano-N′-(5-(2,4-dichlorophenyl)oxo)pentyl)-N″-(4-pyridyl)guanidine,
146) N-cyano-N′-(5-(2,4,6-trichlorophenyl)oxo)pentyl)-N″-(4-pyridyl)guanidine,
147) (E)-N-(6-(4-chlorophenoxy)-hexen-3-yl)-N′-cyano-N″-(4-pyridyl)guanidine,
148) (Z)-N-cyano-N′-(6-phenylhexen-5-yl)-N″-(4-pyridyl)guanidine,
149) (E)-N-cyano-N′-(6-phenylhexen-5-yl)-N″-(4-pyridyl)guanidine,
150) (E,E)-N-cyano-N′-(6-phenylhexa-3,5-dienyl)-N″-(4-pyridyl)guanidine,
151) (Z)-N-cyano-N′-(6-(4-chlorophenyl)hexen-5-yl)-N″-(4-pyridyl)guanidine,
152) N-cyano-N′-(6-phenylhexyn-5-yl)-N″-(4-pyridyl)guanidine,
153) N-cyano-N′-(13-phenyltridecyn-12-yl)-N″-(4-pyridyl)guanidine,
154) N-cyano-N′-(6-phenylhexyn-5-yl)-N″-5-(2-methoxypyridyl)guanidine,
155) N-cyano-N′-(6-phenylhexyn-5-yl)-N″-3-(2-chloropyridyl)guanidine,
156) N-(6-benzoylaminohexyl)-N′-cyano-N″-4-pyridyl guanidine,
157) N-(6-(4-chlorobenzoylamino)hexyl)-N′-cyano-N″-4-pyridyl guanidine,
158) N-(6-(4-chlorobenzoylamino)hexyl)-N′-cyano-N″-(2-methoxy-5-pyridyl)guanidine,
159) N-(6-(4-chlorobenzoylamino)hexyl)-N′-cyano-N″-(2-methyl-4-pyridyl)guanidine,
160) N-cyano-N′-(5-phenylaminocarbonylpentyl)-N″-(4-pyridyl)guanidine,
161) N-(5-(4-chlorobenzoyl)pentyl)-N′-cyano-N″-(4-pyridyl)guanidine,
162) N-(7-(4-chlorobenzoyl)heptyl)-N′-cyano-N″-(4-pyridyl)guanidine,
163) N-(6-(4-chlorobenzoyl)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
164) N-(6-(3-pyridyl-oxo)-1-hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
165) N-(6-(1-imidazolyl)-1-hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
166) N-(6-(2-quinolyl-oxo)-1-hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
167) N-(6-(3-pyridyl)-1-hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
168) N-(6-(3-quinolyl)-1-hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
169) N-(6-(5-pyrimidinyl)-1-hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
170) 1,12-bis(N′-cyano-N″-3-pyridyl guanidyl)-dodecane,
171) 1,10-bis(N′-cyano-N″-4-pyridylguanidine)decane,
172) 2,2′-bis(N′-cyano-N″-3-pyridyl guanidyl)diethyldisulfide, or
173) 1,4-bis(N′-cyano-N″-4-pyridylguanidinemethyl)cyclohexane.
The invention further includes compositions prepared with compounds in Chinese patent applications CN 98805480.9, CN 98805590.2, CN 98805591.0, CN 98805595.3, ZL 02810102.2 and CN 98805594.5 and a cyclodextrin and/or a cyclodextrin derivative.
Where a compound of formula (I) or a tautomer of a compound of formula (I) according to the invention has optical isomers, an R isomer, an S isomer, or a mixture of an R isomer and an S isomer can be used to prepare a composition.
Where a compound of formula (I) or a tautomer of compound of formula (I) according to the invention has diastereoisomers, a Z isomer, an E isomer, or a mixture of a Z isomer and an E isomer can be used to prepare a composition.
A pharmaceutically acceptable salt of a compound of formula (I) or a tautomer of a compound of formula (I) according to the invention refers to a salt prepared with a compound of formula (I) or a tautomer of a compound of formula (I) with a suitable acid, in which the acid includes, but is not limited to one or more than one of the following: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, acetic acid, phosphoric acid, lactic acid, maleic acid, phthalic acid, citric acid, propionic acid, benzoic acid, glutaric acid, gluconic acid, methanesulfonic acid, salicylic acid, succinic acid, tartaric acid, methylbenzenesulfonic acid, aminosulfonic acid, fumaric acid, formic acid, malic acid, ascorbic acid, malonic acid, oxalic acid, mandelic acid, hydroxyacetic acid, benzenesulfonic acid, naphthalene sulfonic acid, trimesic acid and glutamic acid.
A pharmaceutically acceptable salt of a compound of formula (I) or a tautomer of a compound of formula (I) according to the invention can further form a solvate. The solvent with which the pharmaceutically acceptable salt of the compound of formula (I) or the tautomer of the compound of formula (I) can form a solvate is selected from one or more than one of the following: water, ethanol, glycerol, acetone, butanone and polyethylene glycol.
A solvate of a compound of formula (I) or a tautomer of a compound of formula (I) according to the invention refers to a solvate formed with a compound of formula (I) or a tautomer of a compound of formula (I) with one or more than one of the following: water, ethanol, glycerol, acetone, butanone and polyethylene glycol.
The composition comprising a compound of formula (I) disclosed in the invention can be prepared as a medicament for treating proliferative diseases, which include, but are not limited to various cancers, diseases or disorders induced by abnormal cell proliferation. More specifically, the proliferative diseases include, but are not limited to leukemia, acute granulocyte leukemia, chronic myelocytic leukemia, chronic myelocytic leukemia, myelodysplasia, multiple myeloma, Hodgkin's disease or non-Hodgkin's lymphoma, small cell or non-small cell lung cancer, gastric cancer, bowel cancer, colon cancer, rectal cancer, prostate cancer, ovarian cancer, breast cancer, brain cancer, head and neck cancer, urethral carcinoma, renal carcinoma, bladder cancer, melanoma, liver cancer, skin cancer, uterine cancer and pancreatic cancer.
The composition comprising a compound of formula (I) disclosed in the invention can also be used in combination with one or more than one compound to treat proliferative diseases. The composition of the invention can be used simultaneously or sequentially when combined with other compounds. Other compounds which can be used in combination with a composition comprising a compound of formula (I) provided in the invention to treating proliferative diseases include, but are not limited to triazine derivatives such as hexamethylmelamine; enzymes such as asparagine enzyme; antibacterial agents such as bleomycin, dactinomycin, daunorubicin, adriamycin, idarubicin, mitomucin, epirubicin or plicamycin; alkylating agents such as busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, isocyclophosphamide, lomustine, mustine, melphalan, procarbazine or thiotepa; metabolic antagonists such as cladribine, cytarabine, floxuridine, fludarabine, fluorouracil, hydroxyurea, mercaptopurine, methotrexate, gemcitabine, pentostatin or tioguanine; antimitotic agents such as etoposide, paclitaxel, teniposide, vinblastine, vinorelbine or vincristine; hormone drugs such as aromatic enzyme inhibitors e.g. aminoglutethimide; corticosteroids such as dexamethasone, prednison or luteinizing hormone releasing hormone (LH-RH); antiestrogenic agents such as tamaxin, formestane or letrozole; antiandrogen agents such as flutamide; biological response modifiers such as aldesleukin in lymphokine or other interleukins; interferons such as interferon-a; growth factors such as erythropoietin, neupogen or sargramostim; differentiation agents such as vitamin D derivatives e.g seocalcitol; all-trans retinoic acid; immunomodulators such as levamisol; monoclonal antibody; tumor necrosis factor a; or angiogenesis inhibitors. Other compounds more suitable to be used in combination with a composition comprising a compound of formula (I) disclosed in the invention to treat proliferative diseases are selected from one or more than one of the following: paclitaxel, fluorouracil, etoposide, cyclophosphamide, cisplatin, carboplatin, vincristine, gemcitabine, vinorelbine, chlorambucil, adriamycin, melphalan and seocalcitol.
Where a composition comprising a compound of formula (I) disclosed in the invention is used to treat proliferative diseases, the composition can also be used in combination with ionizing radiation.
Where a composition comprising a compound of formula (I) disclosed in the invention is used to treat proliferative diseases, the composition can also be used in combination with medicaments for alleviating side effects of antitumor therapy. The medicaments for alleviating side effects of antitumor therapy include, but are not limited to amifostine, leucovorin and mesna.
The invention further relates to a pharmaceutical preparation comprising a composition comprising a compound of formula (I). The preparation in the invention refers to an appropriate pharmaceutical formulation prepared with a composition comprising a compound of formula (I) alone or along with necessary pharmaceutically acceptable pharmaceutical excipients, such that the preparation is suitable to be applied via a route of administration including, but not limited to oral administration, buccal administration, intravenous administration, intraperitoneal injection, subcutaneous injection, intramuscular injection, nasal drops, eye drops, inhalation, anal administration, vaginal administration, epidermal administration and the like. The appropriate pharmaceutical formulation includes, but is not limited to infusion, water injection, powder injection, lyophilized powder injection, oral solution, syrup, tablet, pill, capsule, granules, gel, soft capsule, suppository, aerosol, cream and the like. The weight of the composition comprising a compound of formula (I) is about 0.1% to 100% by weight of the pharmaceutical preparation. The unit dosage contains about 0.1 mg to 5 g of a compound of formula (I), and more appropriate unit dosage contains about 0.1 mg to 3 g of a compound of formula (I). Unit dosage refers to a unit which can be applied to a patient and can be easily operated and packaged, i.e. a single dosage.
Where the composition comprising a compound of formula (I) disclosed in the invention is prepared as a lyophilized powder injection, a pharmaceutical freeze-dried excipient may be or may not be further added. The excipient is selected from one or more than one of the following: mannitol, sorbierite, sodium chloride, glucose, fructose, sucrose, xylitol and lactose.
Where the composition comprising a compound of formula (I) provided in the invention is prepared as a powder injection, a water injection or a lyophilized powder injection, an appropriate amount of a sterile pharmaceutical diluent, which include, but is not limited to water for injection, physiological saline, glucose water, and other known aqueous carriers, can be added prior to use to prepare a solution preparation for intramuscular injection or intravenous administration.
The invention also discloses a process for preparing a composition comprising a compound of formula (I).
Process 1 The process comprises dissolving a compound of formula (I) in a solvent, adding a cyclodextrin, a cyclodextrin derivative and/or a surfactant with solubilization, and then removing the solvent. The solvent used to dissolve the compound of formula (I) is selected from one or more than one of the following: chloroform, dichloromethane, glycerol, methanol, ethanol, propanol, isopropanol, acetone, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, butanol, ethyl acetate, ethyl formate, formic acid, acetic acid, trifluoroacetic acid, propylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600 and an acidic solution, wherein the acidic solution is selected from the group consisting of hydrochloric acid solution, sulfuric acid solution, nitric acid solution, phosphoric acid solution, formic acid solution, acetic acid solution, methanesulfonic acid solution, benzenesulfonic acid solution, methylbenzenesulfonic acid solution, nitro benzenesulfonic acid solution, ethyl sulfonic acid solution, propanesulfonic acid solution, tris solution, naphthalene sulfonic acid solution and citric acid solution.
Process 2 The process comprises dissolving a compound of formula (I) in a solvent, mixing with a solution of a cyclodextrin, a cyclodextrin derivative and/or a surfactant with solubilization, and then removing the solvent. The solvent used to dissolve the compound of formula (I) is selected from one or more than one of the following: chloroform, dichloromethane, glycerol, methanol, ethanol, propanol, isopropanol, acetone, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, butanol, ethyl acetate, ethyl formate, formic acid, acetic acid, trifluoroacetic acid, propylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600, water and an acidic solution, wherein the acidic solution is selected from a group consisting of hydrochloric acid solution, sulfuric acid solution, nitric acid solution, phosphoric acid solution, formic acid solution, acetic acid solution, methanesulfonic acid solution, benzenesulfonic acid solution, toluenesulfonic acid solution, nitro benzenesulfonic acid solution, ethyl sulfonic acid solution, propanesulfonic acid solution, tris solution, naphthalene sulfonic acid solution and citric acid solution, The solvent used to dissolve the cyclodextrin, cyclodextrin derivatives and/or surfactant with solubilization is selected from one or more than one of the following: water, glycerol, methanol, ethanol, propanol, isopropanol, butanol, chloroform, dichloromethane, acetone, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, ethyl acetate, ethyl formate, formic acid, acetic acid, trifluoroacetic acid, propylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600 and an acidic solution, wherein the acidic solution is selected from one or more than one of the following: hydrochloric acid solution, sulfuric acid solution, nitric acid solution, phosphoric acid solution, formic acid solution, acetic acid solution, methanesulfonic acid solution, benzenesulfonic acid solution, toluenesulfonic acid solution, nitro benzenesulfonic acid solution, ethyl sulfonic acid solution, propanesulfonic acid solution, tris solution, naphthalene sulfonic acid solution or citric acid solution.
Process 3 The process comprises adding a compound of formula (I) into a solution comprising a cyclodextrin, a cyclodextrin derivatives and/or a surfactant with solubilization, and then removing the solvent. The solvent used to dissolve the cyclodextrin, cyclodextrin derivatives and/or surfactant with solubilization is selected from one or more than one of the following: water, glycerol, methanol, ethanol, propanol, isopropanol, butanol, chloroform, dichloromethane, acetone, tetrahydrofuran, dimethylformamide, dimethylsulfoxide, butanol, ethyl acetate, ethyl formate, formic acid, acetic acid, trifluoroacetic acid, propylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene glycol 600 and an acidic solution, wherein the acidic solution is selected from a group consisting of one or more mixed liquor of hydrochloric acid solution, sulfuric acid solution, nitric acid solution, phosphoric acid solution, formic acid solution, acetic acid solution, methanesulfonic acid solution, benzenesulfonic acid solution, toluenesulfonic acid solution, nitro benzenesulfonic acid solution, ethyl sulfonic acid solution, propanesulfonic acid solution, tris solution, naphthalene sulfonic acid solution and citric acid solution.
The feeding molar ratio of a compound of formula (I) to a cyclodextrin or a cyclodextrin derivative is in the range of from 1:0.1 to 1:1000. More appropriate feeding molar ratio of a compound of formula (I) to a cyclodextrin or a cyclodextrin derivative is in the range of from 1:1 to 1:100.
The feeding molar ratio of a compound of formula (I) to a surfactant with solubilization is in the range of from 1:0.001 to 1:1000. More appropriate feeding molar ratio of a compound of formula (I) to a surfactant with solubilization is in the range of from 1:0.005 to 1:100.
In specific embodiments, such as Example 2 and Example 3, HP-β-CD is added during the preparation of a composition and a clear solution can be obtained when the lyophilized powder of the resultant composition is redissolved in Example 2. However, when the conditions in Example 3 are the same as those in Example 2 except that HP-β-CD is not added during the preparation of a composition, the resultant lyophilized powder cannot be redissolved. Therefore, the addition of HP-β-CD can significantly increase the solubility of the compound in Example 2. Similarly, in Example 13 and Example 14, a clear solution can be obtained when the resultant composition is redissolved in Example 14 after adding HP-β-CD during the preparing process in Example 13, while the lyophilized powder in Example 13 cannot be redissolved. Different kinds of cyclodextrins or cyclodextrin derivatives can solubilize the same compound and improve the solubilities of compositions prepared with various processes. Therefore, the composition comprising a compound of formula (I) provided in the invention can significantly improve the solubility of a compound of formula (I) in an aqueous solution.
In order to better illustrate the technical solutions of the invention, the most commonly used HP-β-CD, SBE-β-CD, polysorbate 80, polyethylene glycol-12-hydroxystearate and polyoxyethylene castor oil are used in the following examples. However, the invention is not limited thereby.
CD: cyclodextrin
HP-β-CD: hydroxypropyl-β-cyclodextrin
SDS: sodium dodecylsulphate
mM: mmol/l
SBE7-β-CD: sulfobutylether-β-cyclodextrin with a mean substitution of 7
SBE6.5-β-CD: sulfobutylether-β-cyclodextrin with a mean substitution of 6.5
SBE6-β-CD: sulfobutylether-β-cyclodextrin with a mean substitution of 6
SBE-β-CD: sulfobutylether-β-cyclodextrin
0.1N: 0.1 mol/l
Solubilization tests are carried out with the following compounds in the invention:
Compound 1:
N-cyano-N′-(6-(p-chlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
Compound 2:
N-cyano-N′-(6-(o-chlorophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
Compound 3:
N-cyano-N′-(6-(o-methoxyphenoxy)hexyl)-N″-(4-pyridyl)guanidine,
Compound 4: 1,12-bis(N′-cyano-N″-4-pyridylguanidine)dodecane,
Compound 5:
N-(12-(tert-butoxycarbonylamino)dodecyl)-N′-cyano-N″-(4-pyridyl)guanidine,
Compound 6:
N-(6-((4-chlorobenzoic acid)ester)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine,
Compound 7:
N-cyano-N′-(6-(2-chloro-4-fluorophenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
Compound 8:
N-cyano-N′-(6-(o-bromophenoxy)hexyl)-N″-(4-pyridyl)guanidine,
Compound 9:
N-cyano-N′-(6-((2,6-dichlorophenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
Compound 10:
N-cyano-N′-(6-(o-trifluoromethoxyphenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine,
Compound 11:
N-cyano-N′-(5-(o-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
Compound 12:
N-cyano-N′-(7-(o-chlorophenoxy)heptyl)-N″-(4-pyridyl)guanidine,
Compound 13:
N-cyano-N′-(5-(p-chlorophenoxy)pentyl)-N″-(4-pyridyl)guanidine,
Compound 14:
N-cyano-N′-(8-((o-methoxyphenyl)oxo)octyl)-N″-(4-pyridyl)guanidine,
Compound 15:
N-cyano-N′-(5-((2,4-dichlorophenyl)oxo)pentyl)-N″-(4-pyridyl)guanidine,
Compound 16:
N-cyano-N′-(5-(2,4,6-trichlorophenyl)oxo)pentyl)-N″-(4-pyridyl)guanidine,
Compound 17:
N-cyano-N′-(6-((2,4,6-trichlorophenyl)oxo)hexyl)-N″-(4-pyridyl)guanidine
2.5 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. 21 mg of HP-β-CD was dissolved in the resultant solution. A clear solution was obtained. The solvent was removed by freeze-drying to obtain the desired composition 1.
2.5 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. 21 mg of HP-β-CD was dissolved in the resultant solution. A clear solution was obtained. The pH of the solution was adjusted with 0.1N of sodium hydroxide to such an extent that precipitates were just to generate. The solvent was removed by freeze-drying to obtain the desired composition 2.
2.5 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. A clear solution was obtained. An amount of sodium hydroxide solution which was equal to that in Example 2 was added. The solvent was removed by freeze-drying to obtain the desired composition 3.
2 mg of compound 1 was weighed and dissolved with 2 ml methanol and 0.5 ml DMSO to obtain Control Solution 1.
2 mg of compound 2 was weighed and dissolved with 2 ml methanol and 0.5 ml DMSO to obtain Control Solution 2.
2 mg of compound 3 was weighed and dissolved with 2 ml methanol and 0.5 ml DMSO to obtain Control Solution 3.
After the compositions obtained in Examples 2 and 4-10 were dissolved in water, the concentrations of the composition solutions obtained in each example were determined by HPLC with Control Solution 1 as control.
After the compositions obtained in Examples 12-17 were dissolved in water, the concentrations of the composition solutions obtained in each example were determined by HPLC with Control Solution 2 as control.
After the compositions obtained in Examples 18-24 were dissolved in water, the concentrations of the composition solutions obtained in each example were determined by HPLC with Control Solution 3 as control.
Unless otherwise specified, the HPLC conditions used in the invention are as follows:
Agilent 1200;
Mobile phase: water (12.5 mM K2HPO4, 10 mM SDS, 13% acetonitrile with pH of 2.5 adjusted with phosphoric acid):acetonitrile=60:40, and the gradient changes from the initial ratio of 60:40 to 34:66 in 10 min;
Chromatographic column: PLATISIL™ ODS 5μ 150 ×4.6 mm;
Wavelength of detection: 278 nm;
Flow rate: 1 ml/min;
Column temperature: 40° C.
Table 1 lists the concentrations of the solutions after the compositions obtained in each examples were redissolved.
2.5 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. 5% (V/V) of polysorbate 80 was added in the resultant solution. The pH of the solution was adjusted with 0.1N of sodium hydroxide to such an extent that precipitates were just to generate. The solution was placed for observation and it was found that the solution kept clear for 12 hours.
2.5 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. An amount of 0.1 N sodium hydroxide solution which is equal to that in Example 25 was added. Precipitates produced. The solution was placed for observation and it was found that the precipitates increased during 12 hours.
2 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. 5% (V/V) of polyethylene glycol-12-hydroxy stearate was added in the resultant solution. The pH of the solution was adjusted with 0.1N of sodium hydroxide to such an extent that precipitates were just to generate. The solution was placed for observation and it was found that the solution kept clear for 12 hours.
2 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. The pH was adjusted with an amount of 0.1 N sodium hydroxide solution which is equal to that in Example 27. Precipitates produced. The solution was placed for observation and it was found that the precipitates increased during 12 hours.
2 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. 5% (V/V) of polyoxyethylene castor oil was added in the resultant solution. The pH of the solution was adjusted with 0.1N of sodium hydroxide to such an extent that precipitates were just to generate. The solution was placed for observation and it was found that the solution kept clear for 12 hours.
2 mg of compound 1 was weighed and dissolved with 0.5 ml of 0.1N hydrochloric acid solution. The pH was adjusted with an amount of 0.1 N sodium hydroxide solution which is equal to that in Example 29. Precipitates produced. The solution was placed for observation and it was found that precipitates increased during 12 hours.
2 mg/ml of a clear solution was prepared with 19.4 mg of compound 4 and 0.1N of hydrochloric acid. 3 folds of molar weight of HP-β-CD was added in the resultant solution. The pH was adjusted to about 3 to 4 with 0.1N NaOH solution. The solvent was removed by freeze-drying to obtain the desired composition 31.
1.6 mg of compound 4 was weighed and dissolved in a mixed solution of 1 ml of methanol and 0.5 ml of DMSO to obtain a control solution. 7.66 mg of compound 4 was dissolved in hydrochloric acid solution of pH 4.0 and shaken in an ultrasonic device for 1 hour to prepare a saturated solution. The solubility of compound 4 in hydrochloric acid solution of pH 4.0 was determined by HPLC.
The solubilities of compound 5 to compound 17 in hydrochloric acid solution were determined with the process for determining the solubility in Example 52. The results were listed in Table 2.
After the freeze-dried compositions in Example 31 to Example 51 were redissolved in water, the control solutions used in determination of the solubilities of compound 14 to compound 17 were used as control respectively. The concentrations of the resultant solutions were determined by HPLC. The results were listed in Table 3.
Compound 6 was dissolved with methanol and SBE7-β-CD was dissolved with water. The two resultant solutions were mixed in a ratio of compound 6:SBE7-β-CD=1:2 (molar ratio). The solvent was rotary evaporated to obtain the desired composition 53.
Compound 6 was dissolved with methanol and SBE7-β-CD was dissolved with water. The two resultant solutions were mixed in a ratio of compound 6:SBE7-β-CD=1:4 (molar ratio). The solvent was rotary evaporated to obtain the desired composition 54.
Compound 6 was dissolved with methanol and HP-β-CD was dissolved with water. The two resultant solutions were mixed in a ratio of compound 6: HP-β-CD=1:4 (molar ratio). The solvent was rotary evaporated to obtain the desired composition 55.
Compound 6 was dissolved with methanol and HP-β-CD was dissolved with ethanol. The two resultant solutions were mixed in a ratio of compound 6: HP-β-CD=1:4 (molar ratio). The solvent was rotary evaporated to obtain the desired composition 56.
Compound 6 was dissolved with methanol and SBE7-β-CD was dissolved with water. The two resultant solutions were mixed in a ratio of compound 6: SBE7-β-CD=1:4 (molar ratio). After the mixture was placed at room temperature for 48 hours, the solvent was rotary evaporated to obtain the desired composition 57.
Compound 6 was dissolved with methanol and SBE7-β-CD was dissolved with water. The two resultant solutions were mixed in a ratio of compound 6: SBE7-β-CD=1:4 (molar ratio). After the mixture was placed at room temperature for 48 hours, the solvent was rotary evaporated to obtain the desired composition 58.
Compound 6 was dissolved with methanol and HP-β-CD was dissolved with ethanol. The two resultant solutions were mixed in a ratio of compound 6: HP-β-CD=1:4 (molar ratio). After the mixture was placed at room temperature for 48 hours, the solvent was rotary evaporated to obtain the desired composition 59.
HP-β-CD was dissolved with ethanol. Compound 6 was added into the resultant solution in a ratio of compound 6: HP-β-CD=1:4 (molar ratio). The solvent was rotary evaporated to obtain the desired composition 60.
After the compositions in Example 53 to Example 60 were redissolved in water, the control solution used in determination of the solubility of compound 6 was used as control. The concentrations of the resultant solutions were determined by HPLC. The results were listed in Table 4.
5.41 mg of compound 15 was dissolved with 2.705 ml 0.1N hydrochloric acid. To 1 ml of the resultant solution was added 3 folds of molar weight of HP-β-CD (22.86 mg). The pH of the solution was adjusted to about 3 to 4 with sodium hydroxide. The solvent was removed by freeze-drying to obtain the desired composition 61.
5.41 mg of compound 15 was dissolved with 2.705 ml 0.1N hydrochloric acid. To 1 ml of the resultant solution was added 3 folds of molar weight of SBE7-β-CD (33.08 mg). The pH of the solution was adjusted to about 3 to 4 with sodium hydroxide. The solvent was removed by freeze-drying to obtain the desired composition 62.
4.8 mg of compound 15 was dissolved with 2 ml of acetone to obtain solution A. 246 mg of HP-β-CD was dissolved with 1 ml of water to obtain solution B. 55.76 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 63 comprising compound 15:HP-β-CD=1:3 (molar ratio).
2.49 mg of compound 15 was dissolved with 2 ml of ethanol to obtain solution A. 246 mg of HP-β-CD was dissolved with 1 ml of water to obtain solution B. 28.92 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 64 comprising compound 15:HP-β-CD=1:3 (molar ratio).
4.09 mg of compound 15 was dissolved with 2 ml of methanol to obtain solution A. 246 mg of HP-β-CD was dissolved with 1 ml of water to obtain solution B. 47.51 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 65 comprising compound 15:HP-β-CD=1:3 (molar ratio).
4.8 mg of compound 15 was dissolved with acetone to obtain solution A. 300 mg of SBE7-β-CD was dissolved with 1 ml of water to obtain solution B. 66.15 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 66 comprising compound 15:SBE7-β-CD=1:3 (molar ratio).
2.49 mg of compound 15 was dissolved with ethanol to obtain solution A. 300 mg of SBE7-β-CD was dissolved with 1 ml of water to obtain solution B. 34.32 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 67 comprising compound 15:SBE7-β-CD=1:3 (molar ratio).
4.09 mg of compound 15 was dissolved with 2 ml of methanol. 300 mg of SBE7-β-CD was dissolved with 1 ml of water to obtain solution B. 56.37 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 68 comprising compound 15:SBE7-β-CD=1:3 (molar ratio).
4.8 mg of compound 15 was dissolved with 2 ml acetone to obtain solution A.
245 mg of HP-β-CD was dissolved with 1 ml of ethanol to obtain solution B. 56.0 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 69 comprising compound 15:HP-β-CD=1:3 (molar ratio).
2.49 mg of compound 15 was dissolved with 2 ml ethanol to obtain solution A. 245 mg of HP-β-CD was dissolved with 1 ml of ethanol to obtain solution B. 29.04 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 70 comprising compound 15:HP-β-CD=1:3 (molar ratio).
4.09 mg of compound 15 was dissolved with 2 ml methanol to obtain solution A. 245 mg of HP-β-CD was dissolved with 1 ml of ethanol to obtain solution B. 47.7 μl of solution B was mixed with 0.5 ml of solution A. The solvent was rotary evaporated to obtain the desired composition 71 comprising compound 15:HP-β-CD=1:3 (molar ratio).
After the compositions in Example 61 to Example 71 were redissolved in water, the control solution used in determination of the solubility of compound 15 was used as control. The concentrations of the obtained solutions were determined by HPLC. The results were listed in Table 5.
4.86 mg of compound 15 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 31.73 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 72. To 2 ml of water was added the resultant composition to obtain a clear solution.
3.57 mg of compound 4 was weighed and dissolved with 0.1 M of hydrochloric acid to prepare 2 mg/ml of solution. 27.68 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 73. To 2 ml of water was added the resultant composition into to obtain a clear solution.
6.42 mg of compound 5 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 29.43 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 74. To 2 ml of water was added the resultant composition to obtain a clear solution.
3.79 mg of compound 6 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 31.96 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 75. To 2 ml of water was added the resultant composition to obtain a clear solution.
2.98 mg of compound 8 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 31.64 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1 M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 76. To 2 ml of water was added the resultant composition to obtain a clear solution.
5.12 mg of compound 9 was weighed and dissolved with0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 32.03 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 77. To 2 ml of water was added the resultant composition to obtain a clear solution.
6.36 mg of compound 10 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 31.00 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 78. To 2 ml of water was added the resultant composition to obtain a clear solution.
3.21 mg of compound 16 was weighed and dissolved with0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 30.45 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 79. To 2 ml of water was added the resultant composition to obtain a clear solution.
5.45 mg of compound 17 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 30.01 mg (about 3 folds of molar weight) of SBE6.5-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 80. To 2 ml of water was added the resultant composition to obtain a clear solution.
3.76 mg of compound 1 was weighed and dissolved with 0.1M of hydrochloric acid to prepare 2 mg/ml of solution. 35.04 mg (about 3 folds of molar weight) of SBE6-β-CD was added into the resultant solution with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 81. To 2 ml of water was added the resultant composition to obtain a clear solution.
9.16 mg of compound 16 was weighed and dissolved with 4.58 ml of 0.1M of hydrochloric acid. To 2 ml of the resultant solution was added 44 mg (about 3 folds of molar weight) of HP-β-CD with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 82.
9.16 mg of compound 16 was weighed and dissolved with 4.58 ml of 0.1M of hydrochloric acid. To 2 ml of the resultant solution was added 65 mg (about 3 folds of molar weight) of SBE7-β-CD with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that the precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 83.
8.36 mg of compound 17 was weighed and dissolved with 4.18 ml of 0.1M of hydrochloric acid. To 2 ml of the resultant solution was added 42 mg (about 3 folds of molar weight) of HP-β-CD with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 84.
8.36 mg of compound 17 was weighed and dissolved with 4.18 ml of 0.1M of hydrochloric acid. To 2 ml of the resultant solution was added 63 mg (about 3 folds of molar weight) of SBE7-β-CD with vortexing. 0.1M of sodium hydroxide solution was dropwise added to such an extent that precipitates were just to generate and at the same time the precipitates can disappear. The solvent was removed by freeze-drying to obtain the desired composition 85.
After the compositions in Example 82 to Example 85 were redissolved in water, the control solutions used in determination of the solubility of compound 16 and compound 17 were used as control, respectively. The concentrations of the obtained solutions were determined by HPLC. The results were listed in Table 6.
| Number | Date | Country | Kind |
|---|---|---|---|
| 200910067820.1 | Feb 2009 | CN | national |
| 201010105331.3 | Feb 2010 | CN | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/CN2010/000156 | Feb 2010 | US |
| Child | 13198633 | US |
